Compare Organon & Co. Common Stock (OGN) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Walmart Stores Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Walmart Stores Inc trades at $117.09 (market cap $890.80B). The key difference: Walmart Stores Inc is far larger — about 246.1× Organon & Co. Common Stock's market cap, and Walmart Stores Inc pays the higher dividend (0.88%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Walmart Stores Inc for 101 Days on average.
| OGN | WMT | |
|---|---|---|
Market Cap | $3.62B | $890.80B |
Volume | 2,892,999 | 17,493,315 |
Sector | Health | Consumer Staples |
52-Week High | $13.81 | $134.20 |
52-Week Low | $5.70 | $100.61 |
Typical Hold Time | 0 Days | 101 Days |
Enterprise Value | $11.04B | $953.03B |
Dividend Yield | 0.58% | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Walmart (WMT) trades at $113.08, up 1.55% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $680.99B in 2025, with net income reaching $19.44B, and the company has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion in AI capabilities, e-commerce growth exceeding 50%, and a new Medicare Advantage partnership, signaling strategic initiatives to bolster market share.
The outlook for WMT is positive, supported by robust earnings growth, analyst consensus favoring buys (71%), and a price target of $128.84 implying ~14% upside. Key risks include elevated valuation multiples (P/E 40.68) and rising operational costs, but the company's scale and digital investments provide a competitive edge. Investors should weigh growth prospects against cost pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
